关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
% V8 W5 N& e9 |0 v' C    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
- X4 A7 a: A- p$ G; G  x" h
作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
) B; a, m- m0 j9 o! T1 u- }' _Dear Group,

3 O1 i7 C6 S: M7 Z6 uSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
! t% L6 Y6 ?' V* G/ L/ D8 M0 Q; K$ aafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
$ @4 s0 G6 E$ A9 s4 B$ b4 Vdoes spike up the immune system so I hope more reports come out on this issue.

The remarkable news about Sprycel cessation is that all 3 patients had failed
1 X+ S! E3 o; k' v. \1 Z. J0 e/ LGleevec and Sprycel was their second TKI so they had resistant disease. This is
1 k$ ]7 [* l: [- `% m& ^different from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.
5 f/ J# c: }" L! z
Best Wishes,
  }* f( G6 T+ O  {. ^  IAnjana



Haematologica. 2011 Aug 9. [Epub ahead of print]
# @9 }4 h' ?/ Q) @0 I# LDurable complete molecular remission of chronic myeloid leukemia following
! @  Q' K; \; n: V. s, bdasatinib cessation, despite adverse disease features.
+ v% v1 Z' P8 k1 w/ b' k0 HRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
* h* E! B0 @6 S, Z8 `; ^Adelaide, Australia;
' a$ h- u! z+ q0 y* g8 p
9 o0 r, ~5 G' Y& i+ J  \Abstract
3 Y/ j6 s7 h# L# RPatients with chronic myeloid leukemia, treated with imatinib, who have a
4 N. p& p! {  T+ s9 q. ddurable complete molecular response might remain in CMR after stopping
) x6 A$ H: O/ R/ Z0 R0 ztreatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
+ h3 T: y, J. |) w/ O! {/ D0 |treatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
( ?2 V2 d% B) |characteristics of complete molecular response on dasatinib treatment may be
' s5 Q- ?# Z/ q9 Q4 v" R( V7 E% S  B$ Xsimilar to that achieved with imatinib, at least in patients with adverse
disease features.
2 r# w* \$ \7 M

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
% P1 N( y& h  _1 A    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
& D# I% J8 {3 _& u+ }; l  U. |
作者：来自法国STIM试验
  _7 U% a! o1 }( i" k) @来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事